Sunesis Pharmaceuticals — Merger or Acquisition (January 2021)
23 slides from Sunesis Pharmaceuticals's merger presentation, Jan 7, 2021
Slide 1: Precision Oncology Company Targeting Virus-Associated Cancers
Precision Oncology Company Targeting Virus-Associated Cancers January 2021 Corporate PresentationPrecision Oncology Company Targeting Virus-Associated Cancers January 2021 Corporate Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: expected timing, completion and effects of the proposed merger of Sunesis Pharmaceutics, Inc,
Slide 3: Additional Information on the Proposed Transaction
Additional Information on the Proposed Transaction Additional Information and Where to Find It This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the propos
Slide 4: Leadership Team
Leadership Team Ivor Royston, MD Lisa Rojkjaer, MD Daniel Chevallard, CPA Chief Medical Officer Chief Financial Officer President and Chief Executive Officer Hybritech Douglas Faller, MD, PhD Xiaohu Deng, PhD Robert McRae Chief Scientific Officer Senior VP, Product Development VP, Operations & Strat
Slide 5: 15-20% of Cancers Worldwide Contain Latent Viral Genomes
Introduction to 15-20% of Cancers Worldwide Contain Latent Viral Genomes Viral Infections and Cervical, oropharyngeal cancer Liver cancer Cancer Merkel cell Core, Glioblastoma N53, E6, E7 carcinoma NS5A LT, sT Viral Genomes IE, UL76 HCV HPV MCV CMV Viral Oncogenic Proteins LANA, B & T cell Infection
Slide 6: EBV: Prognostic Significance and Detection
EBV: Prognostic Significance and Detection DLBCL Peripheral T cell lymphoma (PTCL) EBV positivity correlates with shortened survival in DLBCL, PTCL and HL: • Standard of care can extend survival in EBV-negative lymphomas, but is not as + effective in those that are EBV DLBCL Plasmablastic NK/T EBV e
Slide 7: Viracta's Synthetic Lethality Approach Selectively Targets EBV Cancer Cells
+ Viracta’s Synthetic Lethality Approach Selectively Targets EBV Cancer Cells Latency Lethality Induction of Viral Genes EBV is latent in cancer cells and viral Activated GCV induces Nanatinostat (Nstat) induces + kinase genes are silenced apoptosis in EBV cancer cells expression of EBV kinase genes
Slide 8: Viracta: Well-positioned to advance its novel oral therapy for EBV tumors
+ Viracta: Well-positioned to advance its novel oral therapy for EBV tumors + • EBV cancers: Orphan diseases with high unmet medical need, poor prognosis and no approved therapies + • Viracta’s approach: Novel biomarker-directed therapy with oral delivery - targets EBV tumor cells by “Synthetic Leth
Slide 9: EBV Lymphoma Program
+ EBV Lymphoma Program 2021 Corporate Presentation I 9+ EBV Lymphoma Program 2021 Corporate Presentation I 9
Slide 10: Design of Phase 1b/2 Trial in R/R EBV Lymphoma
+ Design of Phase 1b/2 Trial in R/R EBV Lymphoma + • Open-label, dose escalation/expansion study of oral Nstat +VGCV combination in patients with recurrent EBV lymphoma • Dose-ranging Phase 1b (n=25) identified recommended phase 2 dose (RP2D) • Phase 2 expansion cohort (N=30) currently enrolling at
Slide 11: Promising Activity in Heavily Pre-treated, Refractory EBV Lymphomas
+ Promising Activity in Heavily Pre-treated, Refractory EBV Lymphomas • Patients receiving ≥2 prior therapies: 76% • Patients refractory to most recent therapy: 80% • Patients that exhausted all standard therapies: 80% Subtype Enrolled (n) Evaluable B-NHL 10 (22%) 9 B cell ORR 4/9 (44%) DLBCL 7 CR (
Slide 12: Response duration for all evaluable patients
Response duration for all evaluable patients Median duration of response (n=15) by lymphoma subtype (n=35) B-NHL T/NK-NHL Withdrawn for autoSCT ENKTL Withdrawn for autoSCT T-NHL IA-LPD Time, months Withdrawn for CAR-T cell therapy Hodgkin Median duration of response: 10.4 months 2 4 6 8 10 12 14 16
Slide 13: Case Studies: ENKTL and PTCL patients
Case Study #1: 37 y.o. female, extranodal NK/T-cell Lymphoma (ENKTL) nd Refractory to 2 Line ASCT; durable response >13 m and counting… • SMILE (L-asparaginase-containing) plus radiotherapy (1st Line), ASCT (2nd line); refractory to last therapy • Patient was being considered for palliative care • P
Slide 14: Phase 2 dose has a promising safety profile
Phase 2 dose has a promising safety profile Grade 3/4 AEs in ≥2 patients Phase 1b (n=25) Phase 2 (n=21) • Oral regimen was generally well-tolerated All G3/4 All G3/4 • The most common G3/4 AEs were reversible Thrombocytopenia 13 (52%) 8 (32%) 5 (24%) 3 (14%) cytopenias Nausea 10 (40%) 0 7 (33%) 2 (1
Slide 15: EBV Solid Tumor Program
+ EBV Solid Tumor Program+ EBV Solid Tumor Program
Slide 16: Preclinical Proof of Concept for Co-administration of Nstat & VGCV in Solid Tumors
Preclinical Proof of Concept for Co-administration of Nstat & VGCV in Solid Tumors *** *** *** • Annual global incidence of NPC & GC: ** ~190,000 • High unmet need exists, especially for R/R disease • Efficacy of combination approach initially reported + in murine models of EBV NPC and GC using a fi
Slide 17: Towards a phase 1b/2 study in EBV solid tumors
+ Towards a phase 1b/2 study in EBV solid tumors Tumor uptake of oral nanatinostat • High tumor uptake of nanatinostat was shown in murine xenograft models of colorectal cancer • Viracta’s “Synthetic Lethality” advantages: • All-Oral combination therapy • EBV-targeting • Favorable safety profile in
Slide 18: Viracta Therapeutics – Sunesis Pharmaceuticals Merger + Contact Information
Viracta Therapeutics – Sunesis Pharmaceuticals Merger + Contact Information • Viracta Therapeutics and Sunesis Pharmaceuticals agreed to merge in an all-stock transaction and the combined company is expected to trade on Nasdaq Ivor Royston, MD under new symbol VIRX President and CEO • Viracta/Sunesi
Slide 19: Appendix
Appendix 2021 Corporate Presentation I 19Appendix 2021 Corporate Presentation I 19
Slide 20: Pipeline: Innovative Approaches to Virus-associated Cancers
Pipeline: Innovative Approaches to Virus-associated Cancers Program Preclinical Phase 1 Phase 2 Registration Trial Nstat/VGCV for Fast Track Designation (November 2019) Expected 1H2021 + EBV Lymphoma Nstat/VGCV for Expected 2021 + EBV Solid Tumors Other Virus-associated Malignancies Orphan Drug Desi
Slide 21: Single Arm Accelerated Approvals in R/R Lymphoma
Single Arm Accelerated Approvals in R/R Lymphoma Nanatinostat/Valganciclovir comparison to prior single-arm accelerated approvals 25 + ORR and DoR for Nstat/VGCV in EBV tafasitamab/lenalidomide lymphoma compare favorably against zanubrutinib registration data for other accelerated 20 ibrutinib appro
Slide 22: Patients with recurrent EBV lymphomas need more treatment options
+ Patients with recurrent EBV lymphomas need more treatment options Accelerated approval path available given lack of options for patients st nd Subtypes 1 Line SoC 2 Line Options Limitations of Current Treatment Paradigm TL or Salvage • Outlook for refractory patients is bleak DLBCL R-CHOP rd Chemo
Slide 23: Non-evaluable patients (n=9)
Non-evaluable patients (n=9) • Withdrew prior to first disease assessment due to: • AE: 3 (unrelated to study drug) • Hospice: 1 • Patient request: 1 • EBV negative: 1 • No measurable disease at baseline: 1 • Incomplete baseline disease assessment: 1 • No disease assessment performed while on study:
Sunesis Pharmaceuticals — Merger or Acquisition (January 2021) on 6ix